30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

1Q14 Revenue: Orthofix

$101.3MM, -2%

  • BioStim $38.4MM, +0.5%
  • Biologics $13.0MM, -3%
  • Extremity Fixation $27.1MM, +4%
  • Spine Fixation $22.8MM, -11%


  • Growth drivers: stable Spine Stim, improving performance in Physio-Stim, increased ExFix sales in the U.K. and France
  • Biologics decrease attributed to decrease in marketing service fee rate with Musculoskeletal Transplant Foundation from 70% to 65% for Trinity Evolution and Elite
  • Spine decrease primarily due to lower ex-U.S. sales
  • Investments in salesforce and transition of Physio-Stim from ExFix to BioStim will support stabilization of that business
  • Trinity Elite ahead of plan in account conversions from Trinity Evolution
  • 2014 product launches include Centurion posterior cervical system, LoneStar standalone cervical device, Skyhawk lateral system (latter for limited 3Q release)